新型肿瘤药治疗前列腺癌的进展

Progression of novel agents in the management of prostate cancer

前列腺癌是男性常见的恶性肿瘤,高居男性恶性肿瘤发病率及死亡率的第二位,仅次于肺癌。中国前列腺癌患者约70%在初诊时已是晚期,这为我国前列腺肿瘤的治疗带来了巨大的挑战。近年来随着多项大型临床试验的发布,以及精准测序精准诊疗的推进,前列腺癌的治疗格局正在发生迅速改变。本文对前列腺癌领域的最新药物进展进行了梳理,包括第二代新型抗雄激素通路药物、骨靶向治疗、放射性配体疗法、其他小分子靶向药物、免疫治疗等,为前列腺癌的诊疗及药物选择提供优化选择依据。

Prostate cancer is a prevalent male malignancy worldwide ranking second highest incidence after lung cancer.In China,major(about 70%)prostate cancer patients are in the advanced stage when diagnosed and the five year overall survival rate is only 53.8%,which brings great challenges for the treatment.Recent years with the publishing of several large clinical trial results and the advancement of precision medicine,the treatment landscape is changing rapidly.This article presents a review of the recent research including Poly(ADP-ribose)polymerase inhibitors、AR-targeted therapy、Bone-targeting treatments、Prostate-specific membrane antigen theranostics,Immunotherapy and other targeting agents,provides a optimizing strategies for further treatments.